• Is the Comparator in Your Diagnostic Cost-Effectiveness Model “Standard of Care”? Recommendations from Literature Reviews and Expert Interviews on How to Identify and Operationalize It

    May 1, 2024, 00:00

  • Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review

    May 1, 2024, 00:00

  • Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis

    May 1, 2024, 00:00

  • Psychometric Evaluation of the Diary for Irritable Bowel Syndrome Symptoms-Constipation in a Prospective Observational Study

    May 1, 2024, 00:00

  • Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps [Editor's Choice]

    May 1, 2024, 00:00

  • It Is Time to Reconsider the 3% Discount Rate [Editor's Choice]

    May 1, 2024, 00:00

  • Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study [Editor's Choice]

    May 1, 2024, 00:00

  • Development and Valuation of a Preference-Weighted Measure in Age-Related Macular Degeneration From the Vision Impairment in Low Luminance Questionnaire: A MACUSTAR Report

    May 1, 2024, 00:00

  • Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report [Editor's Choice]

    May 1, 2024, 00:00

  • Table of Contents

    May 1, 2024, 00:00

  • Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

    May 1, 2024, 00:00

  • Public Acceptance of Measures to Control Infectious Diseases Under Different Scenarios of Severity and Transmissibility [Editor's Choice]

    May 1, 2024, 00:00

  • EQ-5D-5L Population Norms and Quality-Adjusted Life Expectancy by Sociodemographic Characteristics and Modifiable Risk Factors for Adults in Queensland, Australia

    May 1, 2024, 00:00

  • Toward the Implementation of a Value Framework for Diagnostic Technologies: Operationalization, Piloting, and Validation in Latin America

    May 1, 2024, 00:00

  • Editorial Board

    Apr 1, 2024, 08:56

  • Cost of Illness of Head and Neck Cancer in Sweden

    Apr 1, 2024, 00:00

  • Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework [Editor's Choice]

    Apr 1, 2024, 00:00

  • Evaluating Recall Periods for Patient-Reported Outcome Measures: A Systematic Review of Quantitative Methods

    Apr 1, 2024, 00:00

  • Validation of China Health-Related Outcomes Measures-Cardiovascular Disease

    Apr 1, 2024, 00:00

  • The Cost of Atrial Fibrillation: A Systematic Review

    Apr 1, 2024, 00:00

  • Economic Evaluation of an Enhanced Post-Discharge Home-Based Care Program for Stroke Survivors

    Apr 1, 2024, 00:00

  • The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report

    Apr 1, 2024, 00:00

  • Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients [Editor's Choice]

    Apr 1, 2024, 00:00

  • The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation

    Apr 1, 2024, 00:00

  • Table of Contents

    Apr 1, 2024, 00:00

  • A Comparison of Items and Constructs of Standardized Health-Related Quality of Life and Mental Well-Being Measures

    Apr 1, 2024, 00:00

  • Cost and Utility Estimates per Modified Rankin Scale Score up to 2 Years Post Stroke: Data to Inform Economic Evaluations From a Societal Perspective

    Apr 1, 2024, 00:00

  • Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending [Editor's Choice]

    Apr 1, 2024, 00:00

  • Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy

    Apr 1, 2024, 00:00

  • Benefit-Harm Analysis for Informed Decision Making on Participating in Colorectal Cancer Screening: A Modeling Study

    Apr 1, 2024, 00:00

  • Exploring the Comparability Between EQ-5D and the EQ Health and Wellbeing in the General Australian Population

    Apr 1, 2024, 00:00

  • A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology [Editor's Choice]

    Apr 1, 2024, 00:00

  • Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective

    Mar 1, 2024, 00:00

  • Work Productivity Among Younger Breast Cancer Survivors: The Impact of Behavioral Interventions for Depression

    Mar 1, 2024, 00:00

  • Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?

    Mar 1, 2024, 00:00

  • Identifying the Optimum Strategy for Identifying Adults and Children With Celiac Disease: A Cost-Effectiveness and Value of Information Analysis

    Mar 1, 2024, 00:00

  • Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?

    Mar 1, 2024, 00:00

  • Scoring the Value Assessment Framework for China: A Factorial Survey

    Mar 1, 2024, 00:00

  • Table of Contents

    Mar 1, 2024, 00:00

  • Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs [Editor's Choice]

    Mar 1, 2024, 00:00

  • Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data [Editor's Choice]

    Mar 1, 2024, 00:00

  • Quantifying the Value of Reduced Health Disparities: Low-Dose Computed Tomography Lung Cancer Screening of High-Risk Individuals Within the United States

    Mar 1, 2024, 00:00

  • Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters [Editor's Choice]

    Mar 1, 2024, 00:00

  • Modeling Thyroid Cancer Epidemiology in the United States Using Papillary Thyroid Carcinoma Microsimulation Model

    Mar 1, 2024, 00:00

  • Logical Inconsistencies in the Health Years in Total and Equal Value of Life-Years Gained [Editor's Choice]

    Mar 1, 2024, 00:00

  • Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis

    Mar 1, 2024, 00:00

  • Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany

    Mar 1, 2024, 00:00

  • Editorial Board

    Feb 26, 2024, 08:32

  • Applying Trial-Derived Treatment Effects to Real-World Populations: Generalizing Cost-Effectiveness Estimates When Modeling Complex Hazards [Editor's Choice]

    Feb 1, 2024, 00:00

  • Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States

    Feb 1, 2024, 00:00

  • Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States

    Feb 1, 2024, 00:00

  • Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance

    Feb 1, 2024, 00:00

  • Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non–Small Cell Lung Cancer in ALTA-1L Trial

    Feb 1, 2024, 00:00

  • The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics

    Feb 1, 2024, 00:00

  • Table of Contents

    Feb 1, 2024, 00:00

  • Patient Preferences in Pulmonary Arterial Hypertension, a Latent Class Analysis to Identify Preference Heterogeneity

    Feb 1, 2024, 00:00

  • Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

    Feb 1, 2024, 00:00

  • Author Reply

    Feb 1, 2024, 00:00

  • How Well Does the EQ-5D-Y-5L Describe Children With Intellectual Disability?: “There’s a Lot More to My Child Than That She Can’t Wash or Dress Herself.”

    Feb 1, 2024, 00:00

  • Microsimulation Models on Mental Health: A Critical Review of the Literature [Editor's Choice]

    Feb 1, 2024, 00:00

  • Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report

    Feb 1, 2024, 00:00

  • Influence of Self-Reported Health Impairments on German EQ-5D-5L Values

    Feb 1, 2024, 00:00

  • Patient-Reported Outcome-Based Performance Measures in Alternative Payment Models: Current Use, Implementation Barriers, and Principles to Succeed [Editor's Choice]

    Feb 1, 2024, 00:00

  • Economic Burden and Service Utilization of Children With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis

    Feb 1, 2024, 00:00

  • Editorial Board

    Jan 23, 2024, 09:13

  • Editorial Board

    Jan 9, 2024, 12:13

  • Assessing the Content Validity of Preference-Based Measures in Cancer

    Jan 1, 2024, 00:00

  • Appropriate Categorization of Inequality to Inform Policy Decisions: Estimating Distribution of Lifetime Health Using Alternative Approaches to Socioeconomic Stratification [Editor's Choice]

    Jan 1, 2024, 00:00

  • This Dead or That Dead: Framing Effects in the Evaluation of Health States

    Jan 1, 2024, 00:00

  • A Scoping Review and Taxonomy of Epidemiological-Macroeconomic Models of COVID-19

    Jan 1, 2024, 00:00

  • Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next? [Editor's Choice]

    Jan 1, 2024, 00:00

  • Remembering Victor R. Fuchs, the “Dean” of Health Economics

    Jan 1, 2024, 00:00

  • Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival [Editor's Choice]

    Jan 1, 2024, 00:00

  • Central Venous Access Devices for the Delivery of Systemic Anticancer Therapy: An Economic Evaluation

    Jan 1, 2024, 00:00

  • Two Methods, One Story? Comparing Results of a Choice Experiment and Multidimensional Thresholding From a Clinician Preference Study in Aneurysmal Subarachnoid Hemorrhage [Editor's Choice]

    Jan 1, 2024, 00:00

  • Analyzing Pragmatic Trials to Inform Cost-Effectiveness Analyses

    Jan 1, 2024, 00:00

  • Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefit Manager Discount Programs: The “GoodRx” Model

    Jan 1, 2024, 00:00

  • Negative Drug Pricing in the Context of Cost-Effectiveness Analysis: A Consistency Examination

    Jan 1, 2024, 00:00

  • Testing 2 Alternative Time Trade-Off Methods for Valuation of Children’s Health States

    Jan 1, 2024, 00:00

  • Copyright/Subscription

    Jan 1, 2024, 00:00

  • Table of Contents

    Jan 1, 2024, 00:00

  • Economic Evaluations of Screening Programs for Chronic Kidney Disease: A Systematic Review

    Jan 1, 2024, 00:00

  • Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions [Editor's Choice]

    Jan 1, 2024, 00:00

  • Best Practices for the Electronic Implementation and Migration of Patient-Reported Outcome Measures

    Jan 1, 2024, 00:00

  • EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57

  • EE652 Assessing the Value of Digital Technologies: A Case Study on Humanoid Robot Assistance in Neurorehabilitation

    Dec 23, 2023, 13:57

  • Editorial Board

    Dec 1, 2023, 08:12

  • EPH252 A Systematic Review of the Global Burden of Endometriosis

    Dec 1, 2023, 00:00

  • MSR129 Web Tool Development to Ease the Process of Performing the Meta-Analysis of Kaplan-Meier Curves Published in Various Studies

    Dec 1, 2023, 00:00

  • EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German Dermatologic Cooperative Oncology Group

    Dec 1, 2023, 00:00

  • EPH230 Systematic Literature Review on the Clinical and Economic Burdens of Antimicrobial Resistance in the Japanese Population

    Dec 1, 2023, 00:00

  • EE171 Cost Offset and Budget Impact of Skytrofa for the Treatment of Pediatric Growth Hormone Deficiency: A US Payer’s Perspective

    Dec 1, 2023, 00:00

  • CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)

    Dec 1, 2023, 00:00

  • HTA209 A Review of the Differences Between the New EMA-EUnetHTA Joint Scientific Consultation Versus the Previous Ema-HTA Parallel Scientific Consultation

    Dec 1, 2023, 00:00

  • EE421 Cost-Effectiveness of Empagliflozin in Adult Patients with Chronic Kidney Disease in the Netherlands

    Dec 1, 2023, 00:00

  • OP4 Scientific Communication Plans in Health Economics and Real-World Evidence

    Dec 1, 2023, 00:00

  • HTA362 Being Specific About Analysis Prespecification: Challenges and Opportunities in the Context of EU HTA

    Dec 1, 2023, 00:00

  • HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement

    Dec 1, 2023, 00:00

  • SA34 The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HTA190 The JCA Is Coming: Will the EU Band Together?

    Dec 1, 2023, 00:00

  • PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

    Dec 1, 2023, 00:00

  • RWD6 Costs of Dose Escalation Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Ustekinumab in Portugal

    Dec 1, 2023, 00:00

  • HPR173 Supply-Side Stakeholders’ Opinions and Perspectives on the Development of Medical Tourism in the Region of Thessaly, Greece

    Dec 1, 2023, 00:00

  • EE208 A Total Cost of Care Analysis of Immune-Oncology (IO) Treatments for Unresectable Hepatocellular Carcinoma (uHCC): A Canadian Payer Perspective

    Dec 1, 2023, 00:00

  • EE715 Faricimab Vs. Standard of Care in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Cost-Utility Analysis in Italy

    Dec 1, 2023, 00:00

  • PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year

    Dec 1, 2023, 00:00

  • EE225 Exploring the Value of Country-Specific Cost-Effectiveness Models in Early Stages of Drug Development

    Dec 1, 2023, 00:00

  • EE503 Impact of Managing Multiple Sclerosis Patients in a Private Health Insurance Company in Brazil

    Dec 1, 2023, 00:00

  • HPR164 What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies

    Dec 1, 2023, 00:00

  • MSR61 Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project

    Dec 1, 2023, 00:00

  • HSD97 Exploring European Expert Opinion to Ensure Provision Outcomes in a Post-COVID World

    Dec 1, 2023, 00:00

  • HTA43 Exploring the Link Between Institutional Country-Level Differences and Consideration of Additional Value Elements in HTAs: Results From a Pragmatic Review

    Dec 1, 2023, 00:00

  • EPH163 Dental Preventive Examinations and Caries Prevalence in Children Aged 8-14 Years

    Dec 1, 2023, 00:00

  • EE486 Municipality Costs Due to COVID-19 Infections in Denmark: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • HTA12 Focus on Two Years of Economic Opinions on Solid Cancers: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • MT20 Assessing the Economic Impact of Standardization of Operating Room Workflows Through a Digital Solution

    Dec 1, 2023, 00:00

  • EPH203 The Prevalence of Alopecia Areata in Germany: Results of an Insurance Claims Database Analysis

    Dec 1, 2023, 00:00

  • EE729 Early Intervention With Biosimilars Compared With Leflunomide in Established Rheumatoid Arthritis: A Cost-Effectiveness Analysis in Hong Kong

    Dec 1, 2023, 00:00

  • PCR144 Impact of Oral Corticosteroid Use on Health-Related Quality of Life: Analysis of EQ-5D Data from Navigator

    Dec 1, 2023, 00:00

  • EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel in 3L+ Relapsed/Refractory Large B-Cell Lymphoma in the United States Utilizing Real-World Evidence of Chimeric Antigen Receptor T-Cell Therapies

    Dec 1, 2023, 00:00

  • RWD94 Adaptation and Validation of a Natural Language Processing Algorithm to Use in Electronic Health Records to Identify Patients with Progressive Fibrosing-Interstitial Lung Disease in Spain

    Dec 1, 2023, 00:00

  • EE180 Comparing the Environmental Costs of Differentiated Service Delivery of Antiretroviral Therapy for People Living with HIV in Rural South Africa

    Dec 1, 2023, 00:00

  • HTA122 How Has NICE's Severity Modifier Been Implemented?

    Dec 1, 2023, 00:00

  • P54 Patient-Reported Health Economic Outcomes for Low-Value Medications in Patients Living with Dementia

    Dec 1, 2023, 00:00

  • EE156 Assessing Treatment Costs and Economic Burden of Major Cardiovascular Conditions in Turkiye

    Dec 1, 2023, 00:00

  • RWD84 Building Federated Data Networks With Common Data Models to Generate Insights Through Real-World Evidence Observational Studies in Oncology

    Dec 1, 2023, 00:00

  • HSD114 Treatment Patterns and Adverse Events (AEs) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)

    Dec 1, 2023, 00:00

  • EE537 How Good Are Cost-Effectiveness Model Predictions When Compared to Longer Follow-up Data? An Example of Nivolumab Studies in the First-Line Gastro-Oesophageal Setting

    Dec 1, 2023, 00:00

  • SA59 Clinical Evidence on Acanthamoeba Keratitis Treatments: Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE169 Novel Post-Processing Methods for Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Heat Map and Density-Based Clustering

    Dec 1, 2023, 00:00

  • HTA288 How Wide Ranging Is the Implementation of HTA and Cost-Effectiveness Assessment (CEA) in Major Healthcare Markets

    Dec 1, 2023, 00:00

  • PCR245 Stakeholder Engagement and Expert Consultation on the EuroQol Toddler and Infant Populations (EQ-TIPS) Measure of Health-Related Quality of Life (HRQoL)

    Dec 1, 2023, 00:00

  • PCR267 Health-Related Utilities Associated with Pneumococcal Disease in the Adult Population: What Do We Know?

    Dec 1, 2023, 00:00

  • HTA160 Development of a Web Application for Self-Assessment and Monitoring of Colorectal Surgery Outcome Indicators in the ESCA Study

    Dec 1, 2023, 00:00

  • MT52 Economic and Organizational Advantages of Mrgfus for the Treatment of Essential Tremor in Italy

    Dec 1, 2023, 00:00

  • EE756 Real World Evidence (RWE) Evaluation of Cost Savings through Continuous Vital Sign Monitoring in the Medical-Surgical Ward: A National Health Service (NHS) Experience

    Dec 1, 2023, 00:00

  • EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France

    Dec 1, 2023, 00:00

  • MT60 Digital Health Applications (DIGA) in Germany—An Observation of Clinical Evidence Submissions

    Dec 1, 2023, 00:00

  • CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

    Dec 1, 2023, 00:00

  • EE404 The Economic Burden That Respiratory Syncytial Virus (RSV) Imposes on Irish Hospitals

    Dec 1, 2023, 00:00

  • P52 Validation of an Algorithm to Identify Lines of Therapy Among Adult Patients With Endometrial and Ovarian Cancer in a Real-World Dataset

    Dec 1, 2023, 00:00

  • EPH50 Impact of Dispensed Medication on Mean Age of Death: A Brazilian Public Health System Study

    Dec 1, 2023, 00:00

  • EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • EE526 Health Benefits and Cost-Effectiveness Analysis of Early Cervical Cancer Diagnosis in Bulgaria

    Dec 1, 2023, 00:00

  • HTA169 Highly Sensible Tactics: Strategic Insights for Navigating Highly Specialised Technology (HST) Topic Selection

    Dec 1, 2023, 00:00

  • CO112 Clinical Characteristics and Quality of Life of Thai Moderate to Severe Psoriasis Patients Before Initiating Secukinumab: An Interim Analysis from Prompt Study

    Dec 1, 2023, 00:00

  • EE139 The Need for Economic Systems Modelling to Assess the True Value of Healthcare Innovations: An Application to Influenza Vaccinations

    Dec 1, 2023, 00:00

  • EPH209 Incidence Rates for an Extensive List of Adverse Events of Special Interest in the Pre-COVID-19 and Active COVID-19 Eras: A Comprehensive Source for Representative Historical Background Rates in the US General Population

    Dec 1, 2023, 00:00

  • EPH185 Healthcare Resource Utilization and Cost Burden Assessment of Patients with Myasthenia Gravis in Denmark, Finland, and Sweden

    Dec 1, 2023, 00:00

  • EE276 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Prurigo Nodularis in Adult Patients in Italy

    Dec 1, 2023, 00:00

  • MT69 Early Health Economic Modelling to Support the Development of Lifechamps Digital Platform for Older Cancer Survivors

    Dec 1, 2023, 00:00

  • EE368 Would Initiating Colorectal Cancer Screening from Age of 45 Be Cost-Effective in Germany? An Individual-Level Simulation Analysis

    Dec 1, 2023, 00:00

  • PCR196 Factors Associated with Behaviors Measured By the Rett Syndrome Behavior Questionnaire in Rett Syndrome

    Dec 1, 2023, 00:00

  • EPH169 Examination of the Quality of Life of Patients Underwent Ischemic Stroke and Treated With Intravenous Thrombolytic and Mechanical Thrombectomy Recanalization Intervention

    Dec 1, 2023, 00:00

  • HPR182 Oncology Combination Market Access Conundrum in Europe

    Dec 1, 2023, 00:00

  • CO22 Healthcare Resource Utilization (HCRU), Effectiveness and Safety of Trifluridine/Tipiracil in Treatment of Refractory Metastatic Colorectal Cancer in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2023, 00:00

  • MSR25 Uncertain About Uncertainty in Matching-Adjusted Indirect Comparisons (MAIC)? A Simulation Study to Compare Methods for Variance Estimation

    Dec 1, 2023, 00:00

  • EE350 Budget Impact of Memantine for Alzheimer's Patient in the United States

    Dec 1, 2023, 00:00

  • Methodological Statistical Research

    Dec 1, 2023, 00:00

  • EPH233 Estimation of the Epidemiological and Economic Burden of RSV and Influenza Infection in the Hospital Setting Among Adults 65 Years and Older in France

    Dec 1, 2023, 00:00

  • RWD147 Real-World Data of Therapeutic Inertia in Diabetes in a Health Care Intitution

    Dec 1, 2023, 00:00

  • SA64 Systematic Literature Review of Measurement and Valuation Methods for Societal Costs: A Focus on Cost-Effectiveness Analyses of Three Types of Disease Potentially Associated with High Spillover Effects

    Dec 1, 2023, 00:00

  • RWD93 Quantifying Trends in Price Setting for Traditional and Innovative Advanced Rare Disease Therapies

    Dec 1, 2023, 00:00

  • EE351 Using Social Return on Investment to Capture the Broader Impact of Medicines: Advanced Parkinson's Disease Example

    Dec 1, 2023, 00:00

  • EE580 New Anti-CGRP in Fran Estimated Financial Impact of Eptinezumab in Hospitals, a Prospective Stake

    Dec 1, 2023, 00:00

  • PCR130 Factors Associated With Adjuvant Treatment Options in Resected Stage III Melanoma, From a Patient and Physician Perspective: Preference Assessment Using the Discrete Choice Experiment Method (Pamela Study)

    Dec 1, 2023, 00:00

  • The Impact of Cancer Screening Programs on Population Health Outcomes

    Dec 1, 2023, 00:00

  • P12 Screen-Detected Breast Cancers Have Improved 5-Year Disease Free Interval Compared to Interval and Non-Screen-Related Breast Cancer, Taking Lead Time into Account

    Dec 1, 2023, 00:00

  • PCR226 Health Related Quality of Life and Health Utility Values Across Different Levels of Physically Distancing Behaviors to Avoid COVID-19 in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • EPH155 Burden of Clinical Syndromes Associated with Pneumococcal Disease in Peru: A 2019 Perspective

    Dec 1, 2023, 00:00

  • EPH258 Treatment Pattern of Pemphigus Vulgaris in UK : A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

    Dec 1, 2023, 00:00

  • EE405 Cost-Effectiveness of Single-Inhaler Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium vs Other Open or Single-Inhaler Triple Therapies in Adult Patients with Uncontrolled Asthma in England

    Dec 1, 2023, 00:00

  • MSR81 When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed by Immature Data

    Dec 1, 2023, 00:00

  • MT35 The Impact of Patient Engagement with a Digital Diabetes Solution on All-Cause Healthcare Resource Utilization Rates and Charges

    Dec 1, 2023, 00:00

  • EPH234 Shedding Light into the Dark of Unknown Cost-of-Illness and Burden-of-Disease Associated with RSV across Age Groups in Austria

    Dec 1, 2023, 00:00

  • HSD77 The Impact of the COVID-19 Pandemic on Patient Flow and Key Performance Indicators (KPIS) of Hippocration General Hospital of Athens

    Dec 1, 2023, 00:00

  • HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD

    Dec 1, 2023, 00:00

  • HSD31 Impact and Management of Comorbidities in People With Obesity: A Multinational Survey

    Dec 1, 2023, 00:00

  • EE609 Economic Evaluation and Return-on-Investment (ROI) of Fostering Physical Activity Policies (Simulation With Two Different Tools)

    Dec 1, 2023, 00:00

  • HSD2 Using Automated Data Extraction Methods to Understand the Evolution of Insulin Prescribing in the UK between 2021 and 2022

    Dec 1, 2023, 00:00

  • EE124 Analysis of the Use of the Haute Autorité De Santé (HAS) Opinions by Hospital Pharmacists in France

    Dec 1, 2023, 00:00

  • EE481 Cost-Effectiveness Analysis of Upadacitinib in Patients with Moderately to Severely Active Ulcerative Colitis in Greece

    Dec 1, 2023, 00:00

  • HPR115 Patient Access Network: Multi-Stakeholder Shared Policy Strategies for Medical Device Access

    Dec 1, 2023, 00:00

  • CO113 Impact of Clinical Pharmacist-Led Intervention on Somatic Cell Therapy Medicinal Product Circuit in Portugal

    Dec 1, 2023, 00:00

  • HPR75 What Percent of the Growth in Annual French Social Health Insurance Budget Is Attributed to New Health Products? An Estimation Based on a Retrospective Review of Budget Impact Analyses

    Dec 1, 2023, 00:00

  • RWD60 APNEE Study: A Challenge to Identify Patients Treated with Dupilumab for Chronic Rhinosinusitis with Nasal Polyps (CRSWNP) in Real-Life Settings in France

    Dec 1, 2023, 00:00

  • EE308 Cost-Utility Analysis of Universal Neonatal Screening for Critical Congenital Heart Disease Based on Pulse Oximetry in Spain

    Dec 1, 2023, 00:00

  • PCR212 A Novel Approach to Capturing Real-World Reasons Behind Use and Satisfaction of NVX-CoV2373 Booster Use Among German Adults: Direct-to-Patient Enrollment

    Dec 1, 2023, 00:00

  • Expanding Data Sources: Creative Use of Data in Health Economics Analyses

    Dec 1, 2023, 00:00

  • MSR90 Is the Current Chatgpt Able to Gatherarticles for HEOR Literature Review

    Dec 1, 2023, 00:00

  • EPH45 Exploring the Pandemic's Impact: An Examination of Adolescent and Adult Vaccination Rates in Different Countries During COVID-19

    Dec 1, 2023, 00:00

  • MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials

    Dec 1, 2023, 00:00

  • HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • EE439 Public Health Impact of the Pediatric Immunization Program in the Netherlands

    Dec 1, 2023, 00:00

  • EE218 Budget Impact and Cost Minimization Analysis of Phesgo ® (Trastuzumab + Pertuzumab SC) for the Treatment of HER2+ Breast Cancer in the Chilean Public Health System

    Dec 1, 2023, 00:00

  • EE256 Economic Burden of Geographic Atrophy: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EPH251 Subtype Distribution of Amyloidosis in the United States: Insights from an Electronic Health Records Database Analysis

    Dec 1, 2023, 00:00

  • RWD156 Real-World Progression Patterns in First and Second Lines of Systemic Therapy for Endometrial Cancer

    Dec 1, 2023, 00:00

  • HTA299 A Review of NICE Technology Appraisals of Oncology Treatments in the Past 2 Years – Model Approaches, End of Life Status, and Recommendation Decisions

    Dec 1, 2023, 00:00

  • EE193 Evaluating Clinical Benefits of Vertebral Body Stenting in Treating Osteoporotic Vertebral Compression Fracture: A Physician Survey

    Dec 1, 2023, 00:00

  • PT9 Harnessing the Potential of Natural-Language Processing and Interconnected Data Streams for Complex Diseases in the Hospital Setting: Lupus Case Study in France (LUPUS REAL)

    Dec 1, 2023, 00:00

  • EPH19 Mental Health Disparities for Young Adults with Arrest Histories in the United States

    Dec 1, 2023, 00:00

  • RWD150 A Prescription Pattern of HIV First-Line Tenofovir Alafenamide-Based Single-Tablet Regimens: A Multi-Institutional Study in Taiwan

    Dec 1, 2023, 00:00

  • EE665 Evaluation of Resource Use and Costs of Pertuzumab and Trastuzumab Formulations in HER2- Positive Breast Cancer

    Dec 1, 2023, 00:00

  • HSD25 Patients’ Satisfaction from Primary Healthcare Services in 1ST Local Health Unit (LHU) of N. Philadelphia-N. Chalkidona Municipality Greece

    Dec 1, 2023, 00:00

  • SA49 Capturing Real-World Evidence Alongside Trial Evidence in HTA-Specified Systematic Literature Review: Optimizing Search Strategies across the Totality of Evidence Required

    Dec 1, 2023, 00:00

  • PCR207 A Vignette Study to Derive Health-Related Quality of Life Weights for Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Receiving Third Line Therapy in the United Kingdom

    Dec 1, 2023, 00:00

  • EPH265 Updated Estimations of the HPV Vaccination Deficit Among Girls in Gree Early Signs of Recovery?

    Dec 1, 2023, 00:00

  • MSR11 Performance of Progression-Based and Time-to-Death Utility Analysis Methods and Their Implications on Economic Models: A Targeted Review

    Dec 1, 2023, 00:00

  • PCR52 Use of Patient Reported Outcomes in Key Trials Supporting Marketing Authorisation: 5-Year Analysis of Company Evidence Submitted for National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA)

    Dec 1, 2023, 00:00

  • MT26 Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe

    Dec 1, 2023, 00:00

  • SA17 Application of CPRD Data in NICE Submissions: Model Inputs for Functional Health States

    Dec 1, 2023, 00:00

  • HTA363 Impact of ASMR Changes on List Prices: An Analysis of HAS Re-Evaluations

    Dec 1, 2023, 00:00

  • HTA18 Challenges of Identifying Health Utility Data for Patients With Penta-Refractory Multiple Myeloma to Inform HTA Reimbursement Discussion for Newer Treatment Options

    Dec 1, 2023, 00:00

  • P31 Evidence Supporting Regulatory Withdrawals and Quantifying Their Impact on Public Health

    Dec 1, 2023, 00:00

  • EE328 Healthcare Costs in Patients With Hepatic Encephalopathy Receiving Rifaximin-α Treatment in the IMPRESS-II Study

    Dec 1, 2023, 00:00

  • PCR224 Corticosteroids Usage Impact on Inflammatory Bowel Disease Patients, in Portugal

    Dec 1, 2023, 00:00

  • EE648 Systematic Review of the Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy

    Dec 1, 2023, 00:00

  • EE445 Economic Evaluation of Alternative Measles-Mumps-Rubella Childhood Vaccination Schedules in Denmark

    Dec 1, 2023, 00:00

  • OP20 Carer Health-Related Quality of Life in Health Technology Assessments: Process Recommendations for Determining Relevance, Data Collection, and Inclusion in Health-Economic Models

    Dec 1, 2023, 00:00

  • HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome

    Dec 1, 2023, 00:00

  • EPH207 The Adverse Event Profiles of Modafinil in Approved Indications and Off-Label Use for Major Depressive Disorder: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE414 Incremental Costs of Abrocitinib Compared to Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Denmark

    Dec 1, 2023, 00:00

  • PT13 An Evaluation of the Impact of Evidence Grouping on Certainty Rating When Performing a Grade Assessment Without a Meta-Analysis

    Dec 1, 2023, 00:00

  • HTA278 Risky Business: How Does Risk of Study Bias Impact Health Technology Assessment Submissions?

    Dec 1, 2023, 00:00

  • EE687 Cost Analysis of Prostav®: A New Telomere-Based Biomarker for the Early Detection of Prostate Cancer Available in Europe

    Dec 1, 2023, 00:00

  • SA24 Can an Integrated Systematic Literature Review (SLR) Database Improve the Speed of Title and Abstract (TIAB) Review? A Case Study Using Multiple Myeloma (MM) Projects in Interventional and Real-World Evidence (RWE) Evidence

    Dec 1, 2023, 00:00

  • SA19 Biologics Sequencing in Clinical Units (BISCUITS): UK IBD Registry Agile Research

    Dec 1, 2023, 00:00

  • SA27 Menopause: More Than Just Vasomotor Symptoms

    Dec 1, 2023, 00:00

  • EPH167 The Conceptualization of Cardiometabolic Disease Policy Model in the UK

    Dec 1, 2023, 00:00

  • EPH101 Assessing the Relative Benefits Associated With Developing Vaccines for Nipah Virus Infection and Rift Valley Fever From Local, National, and Global Perspectives

    Dec 1, 2023, 00:00

  • HPR46 Payers’ Perceptions of Current Policy Approaches to Address Antimicrobial Resistance in Europe

    Dec 1, 2023, 00:00

  • MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial

    Dec 1, 2023, 00:00

  • RWD132 Impact of Exacerbations on Disease Burden of COPD: A Retrospective Observational Database Cohort Study in Tianjin, China

    Dec 1, 2023, 00:00

  • EE78 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment Following Complete Resection and Platinum-Based Chemotherapy in Adult Patients With Early-Stage Non-Small Cell Lung Cancer With a High Risk of Recurrence

    Dec 1, 2023, 00:00

  • EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US

    Dec 1, 2023, 00:00

  • EPH154 Modeled Head-to-Head Comparison of Nirsevimab and Rsvpref Maternal Vaccine in the US

    Dec 1, 2023, 00:00

  • EE327 Cost-Effectiveness of Teduglutide in Adult and Pediatric Patients with Short Bowel Syndrome in Argentina: A Markov Model Analysis

    Dec 1, 2023, 00:00

  • EE505 Cost-Effectiveness of Ofatumumab in Treatment of Relapsing Multiple Sclerosis in Turkey

    Dec 1, 2023, 00:00

  • HPR152 Evolution of the Use of Medicines in Special Situations and Management Measures for Their Rational Use

    Dec 1, 2023, 00:00

  • HTA290 Environmental Sustainability in HTA: Are HTA Bodies Applying Environmental Criteria in Their Decision-Making?

    Dec 1, 2023, 00:00

  • PCR261 Uncovering Patient-Reported Outcome Differences Between Undiagnosed and Diagnosed Individuals With Moderate to Severe Psoriasis in Europe

    Dec 1, 2023, 00:00

  • PCR18 Humanistic Burden in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE341 Cost-Utility Analysis of a Multi-Center, Parallel Group Randomized Controlled Trial of an Adapted Parenting Intervention (EPICC-ID) to Reduce Challenging Behavior in Pre-Schoolers with Moderate to Severe Intellectual Disability

    Dec 1, 2023, 00:00

  • EE594 Comparison of the Clinical and Economic Impact of Two COVID-19 Vaccines in Immunocompromised Patients in France

    Dec 1, 2023, 00:00

  • PCR204 Impact of Roflumilast Foam 0.3% on Patient-Reported Quality of Life in Seborrheic Dermatitis: An Analysis of Stratum Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

    Dec 1, 2023, 00:00

  • RWD50 Evaluation and Improvement of a NHDS Algorithm to Detect Patients With Metastatic Breast Cancer and HER2+ Status Using a RWE NLP-Powered Solution

    Dec 1, 2023, 00:00

  • HTA259 Exploring Collaboration on HTA Methodology for Medical Technologies in the Dutch ZonMw HTA Methodology 2021-2024 Subsidy Program

    Dec 1, 2023, 00:00

  • EE36 Economic Burden of Adults Hospitalized with Respiratory Syncytial Virus Infection in Spain, 2016–2019

    Dec 1, 2023, 00:00

  • HTA152 Multidimensional Evaluation of Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2023, 00:00

  • EE508 Cost Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small Cell Lung Cancer in Italy

    Dec 1, 2023, 00:00

  • EE583 Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

    Dec 1, 2023, 00:00

  • EE717 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France

    Dec 1, 2023, 00:00

  • EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye

    Dec 1, 2023, 00:00

  • MSR3 Comparing Statistical Adjustments to Correct Misclassification of Respiratory Syncytial Virus Infections (RSV) in Claims Data

    Dec 1, 2023, 00:00

  • MT12 Comparison of Hospital Case Characteristics of Popliteal Artery Aneurysm Repair with ePTFE Covered Stent Grafts with a Heparin Bioactive Surface and Open Surgical Bypass: Highlights from the 2021 Hospital Dataset in Germany

    Dec 1, 2023, 00:00

  • HPR212 The Use of Managed Entry Agreements (MEAs) for Accessing Innovative Health Technologies

    Dec 1, 2023, 00:00

  • PCR153 Pace CKD: The Impact of Chronic Kidney Disease and Dialysis on Caregivers Financial Status, and Work Productivity: Results from a Multinational Survey

    Dec 1, 2023, 00:00

  • CO31 Progressive Pulmonary Fibrosis: A Modelling Analysis of Long-Term Progression Based on Inbuild

    Dec 1, 2023, 00:00

  • PCR119 The CaOa-QoL-TS: Development and Validation of an Owner-Completed Health-Related Quality of Life and Treatment Satisfaction Measure in Canine Osteoarthritis

    Dec 1, 2023, 00:00

  • EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France

    Dec 1, 2023, 00:00

  • HTA174 Single-Arm Studies in Rare Diseases and Statistical Methods to Mitigate Lack of Comparative Data: What Kind of Assessment Is More Successful for the French HTA Body?

    Dec 1, 2023, 00:00

  • EE292 Cost Effectiveness Analysis of Recombinant Zoster Vaccine Among 50 Years Old and Older in Sweden

    Dec 1, 2023, 00:00

  • HPR204 Reimbursement Status of Centrally Authorized Drugs in Spain per Therapeutic Area and Orphan Designation

    Dec 1, 2023, 00:00

  • EE684 Economic Evaluation of Focal Therapy Used in the Treatment of Prostate Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • MSR130 Current Trends in Quantitative Bias Analysis for Unmeasured Confounders: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • RWD122 First and Second Line Treatment Choices for Endometrial Cancer: ECHOS-A Real-World Study

    Dec 1, 2023, 00:00

  • CO83 Disease Burden of Moderate to Severe Ulcerative Colitis in Chinese Patients Under Current Care: A Model Simulation Study

    Dec 1, 2023, 00:00

  • HPR52 Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action

    Dec 1, 2023, 00:00

  • HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries

    Dec 1, 2023, 00:00

  • P7 International Reference Pricing and Joint Clinical Assessments—How Will European-Level HTA Evaluations Impact International Reference Pricing and Launch Sequencing?

    Dec 1, 2023, 00:00

  • EPH106 Intercultural Approach and Knowledge of Migrant Health Policy in Healthcare Teams and Migrants in Chile

    Dec 1, 2023, 00:00

  • HPR28 Health Technology Assessment of New Drugs in Spain: Understanding the Evaluators’ Evidence Needs

    Dec 1, 2023, 00:00

  • HSD47 Value for Money of Multidisciplinary Programs for Integrated Care in Dialysis: Being Actively Involved and No Merely Listed Matters

    Dec 1, 2023, 00:00

  • HPR169 The Impact of Exercise on Health Expenditure in Children

    Dec 1, 2023, 00:00

  • EPH61 Epidemiology of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study

    Dec 1, 2023, 00:00

  • HSD129 Does Digital Healthcare Improve the Utilization of Public Hospitals in the Emirate of Dubai?

    Dec 1, 2023, 00:00

  • EPH248 Varying Latency Impact on Incidence of Second Primary Malignancy Among Patients with B-Cell Malignancy

    Dec 1, 2023, 00:00

  • EE178 A Targeted Literature Review of Cost-Utility Analyses for Ulcerative Colitis/Crohn’s Disease Treatment

    Dec 1, 2023, 00:00

  • PCR253 The Burden of Persistent Cough in Idiopathic Pulmonary Fibrosis (IPF) and Other Interstitial Lung Diseases (ILD): A Systematic Evidence Synthesis

    Dec 1, 2023, 00:00

  • HTA47 An Overview of the Challenges in the HTA of Interventions Involving Healthcare Reorganisation

    Dec 1, 2023, 00:00

  • EE188 A Retrospective Cohort Comparing the Tuberculosis Diagnosis Related Costs and Health Resource Use (HRU) Using a Rapid Nucleic Acid Amplification (NAA) Test Vs. Conventional Tests in China, Followed By a Budget Impact Model

    Dec 1, 2023, 00:00

  • Medication Use and Its Consequences

    Dec 1, 2023, 00:00

  • EE521 Economic Evaluation of Trastuzumab Deruxtecan for HER2+ Advanced Gastric Cancer Patients

    Dec 1, 2023, 00:00

  • SA29 Evaluating the Adherence to ISPOR Guidelines in Globally Published Budget Impact Analyses of New Drugs: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • RWD154 Using Real World Evidence from the UK MS Register to Support Optimal Healthcare Decision Making

    Dec 1, 2023, 00:00

  • CO89 Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS)

    Dec 1, 2023, 00:00

  • EE396 Economic Evaluation of PD-1 Blockers in Merkel Cell Carcinoma: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • SA12 Discrepancy of Health State Utility Values in Cost-Utility Analyses of Interventions Against Infectious Diseases in Older Adults

    Dec 1, 2023, 00:00

  • EE174 Evaluating the Budget Impact of the Co-Existence of Oral and Injectable Forms of Semaglutide in the Saudi Public Healthcare System

    Dec 1, 2023, 00:00

  • EE69 Cost-Utility Analysis of Lorlatinib for First-Line Treatment for ALK Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • CO37 Inventory-Facilitated Goal Setting Interview Conducted by Disease Experts Yields a Broader Range of Goal Areas

    Dec 1, 2023, 00:00

  • EPH254 Changes in Asthma-Related Healthcare Resource Use in Asthma Patients in the United States During the COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • EPH274 Health-Related Quality of Life in a Large Cohort of Adult Patients With Sickle Cell Disease in France (The DREPAtient Study)

    Dec 1, 2023, 00:00

  • EPH136 Treatment Patterns and Epidemiological Characteristics in Adult Patients With III-IVB HNSCC From a Reference Center in Mexico

    Dec 1, 2023, 00:00

  • CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity

    Dec 1, 2023, 00:00

  • HPR217 Stakeholders' Perspectives on the Unmet Medical Need Concept: A EU Pharmaceutical Strategy Survey Analysis

    Dec 1, 2023, 00:00

  • EE685 Screen-and-Treat Cervical Cancer Screening Strategy Using High-Risk HPV Testing: Early Evaluation for Uganda

    Dec 1, 2023, 00:00

  • EPH105 Effects of Abortion Debate on Fertility Intentions of Women of Childbearing Age

    Dec 1, 2023, 00:00

  • EE107 Estimating EQ-5D Utilities From the Facial Vitiligo Area Scoring Index (F-VASI) in Vitiligo Patients Using a Mapping Algorithm Applied to 2 Pooled Randomized Controlled Trials

    Dec 1, 2023, 00:00

  • SA47 Exploring the Use of Health Technology Assessment in Uganda’s Health Policy and Financing Decision-Making Processes

    Dec 1, 2023, 00:00

  • RWD11 Real-World Persistence on Cladribine Tablets of Patients with RMS over 4 Years Based on Claims Data

    Dec 1, 2023, 00:00

  • EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR207 Moving to Outcomes-Based Agreements in Algeria: Sharing Experiences Between Saudi Arabia and Algeria

    Dec 1, 2023, 00:00

  • HTA97 Exploring the Value of RWD Collected From Early Access Programs to Support HTA Decision-Making

    Dec 1, 2023, 00:00

  • EE163 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for Primary Prevention in China

    Dec 1, 2023, 00:00

  • HTA246 A QALY Is Not a QALY When It Comes to Health Technology Appraisals of Pediatric Rare Diseases

    Dec 1, 2023, 00:00

  • EPH44 Temporary Soft Tissue Coverage in Burn Patients - Which Materials Are Used - and By Whom? Analysis of German Billing Data

    Dec 1, 2023, 00:00

  • EPH201 Epidemiology of Actinic Keratosis in Fran A General Population Survey (REAKT STUDY)

    Dec 1, 2023, 00:00

  • HTA315 Implications for Rare Diseases: NICE Guidance and Outcomes on Implementing Bayesian Borrowing Approaches for External Control Data

    Dec 1, 2023, 00:00

  • EE418 Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Treating Iron Deficiency Anemia in Norwegian Patients With Inflammatory Bowel Disease

    Dec 1, 2023, 00:00

  • PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study

    Dec 1, 2023, 00:00

  • PCR273 Perceptions, Attitudes, and Satisfaction with Private Pharmacies in Gree Results from a Nationwide Survey

    Dec 1, 2023, 00:00

  • RWD67 The Health Resource Utilization and Medical Costs of Cataract Surgery in Pediatric Patients: A National Population-Based Study in a Korea

    Dec 1, 2023, 00:00

  • EPH90 The Increasing Incidence of Respiratory Syncytial Virus (RSV) in Ireland

    Dec 1, 2023, 00:00

  • HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

    Dec 1, 2023, 00:00

  • RWD21 Impact of Haemophilia Severity on Healthcare Resource Usage: Results from a Multinational Real-World Survey

    Dec 1, 2023, 00:00

  • HTA75 Evaluation of the Clinical and Economic Effectiveness of Continuous Glucose Monitoring in Adults With Type 1 Diabetes Mellitus in the Healthcare System of the Republic of Kazakhstan

    Dec 1, 2023, 00:00

  • EPH95 Claims Data Analysis of the Prevalence and Healthcare Resource Utilization of Chronic Kidney Disease-Associated Pruritus in German Hemodialysis Patients

    Dec 1, 2023, 00:00

  • HSD130 Development of a Risk-Adjusted in-Hospital Complication Rate (RAICR) Using Machine Learning Methods

    Dec 1, 2023, 00:00

  • P48 New NICE Proportionate Approaches: Are They Any Faster or More Successful?

    Dec 1, 2023, 00:00

  • EPH63 Obesity Related Complications: Can America Be Europe's Canary in the Coal Mine?

    Dec 1, 2023, 00:00

  • PCR213 Bridging the Practice to Theory Gap: Uncovering and Addressing Barriers and Facilitators to Evaluation of Patient Support Programs by the Pharmaceutical Industry

    Dec 1, 2023, 00:00

  • EPH21 An Assessment of Validated Algorithms for Identifying Multiple Sclerosis Cases, Subtypes, and Relapses in Real-World Databases: A Systematic Review

    Dec 1, 2023, 00:00

  • CO110 Systematic Literature Review and Network Meta-Analysis to Assess the Comparative Efficacy of Topical Fixed-Dose Combinations for Moderate to Severe Acne Vulgaris as Measured By Lesion Counts

    Dec 1, 2023, 00:00

  • PT18 Novel Approaches to Unify Multi-State Transition Modelling Methods and Develop a Synthetic English Population to Support Health Economic Evaluation Studies

    Dec 1, 2023, 00:00

  • EPH99 Public Health Impact of Replacing Monovalent and Quadrivalent Meningococcal Vaccines By Pentavalent Vaccine in the United States

    Dec 1, 2023, 00:00

  • EE60 An Overview of Systematic Reviews of Economic Evaluations on Cancer Screening: Landscape, Quality, and Recommendations

    Dec 1, 2023, 00:00

  • EE284 A Qualitative Primary Market Research Study on the Economic Investment of Scaling up Bariatric Surgery Capacity Within the NHS

    Dec 1, 2023, 00:00

  • HTA53 Proportionally Quicker or Easier? International Comparison of NICE’s Proportionate Approach to Technology Appraisals (PATT) With Global Peers

    Dec 1, 2023, 00:00

  • HPR13 Unmet Needs in Rare Diseases: Insights on Definitions and Methodological Challenges From a Grey Literature Review

    Dec 1, 2023, 00:00

  • HSD36 Impact of Non-Medical Factors on Patterns of Treatment in Patients With Cancer: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH250 Clinical Characteristics of Generalized Pustular Psoriasis Flares in the Real-World Setting

    Dec 1, 2023, 00:00

  • SA36 Safety, Efficacy, Quality of Life, and Treatment Dynamic of Conventional Therapies for Adults and Adolescents Suffering From Eosinophilic Esophagitis, a Type 2 Inflammatory Disease: Qualitative and Quantitative Synthesis

    Dec 1, 2023, 00:00

  • MSR107 Estimating Optimal Personalized Treatment Sequencing for Patients with Multiple Myeloma Using Reinforcement Learning

    Dec 1, 2023, 00:00

  • OP15 Analysis of the Multidisciplinary Approach for the Management of Patients Affected by Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia in Italy

    Dec 1, 2023, 00:00

  • P32 Implementation of Early Access Reform in France and Access to Innovation: Impact in Terms of Number of Drugs, Patients Treated, and Cost

    Dec 1, 2023, 00:00

  • CO142 A Retrospective Study Characterizing Age at Key Clinical Disease Indicators Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • EE239 How to Consider Caregiver Health-Related Quality of Life in a Cost-Effectiveness Analysis? An Illustration with Dupilumab for the Treatment of Severe Atopic Dermatitis in Infants in France

    Dec 1, 2023, 00:00

  • EE730 Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics in Eosinophilic-Associated Diseases

    Dec 1, 2023, 00:00

  • EPH46 Validation of Dynamic Transmission Model for Varicella Immunization Program in Germany

    Dec 1, 2023, 00:00

  • MSR67 Art or Science? Selecting Utility Evidence for Decision-Analytic Models Containing Multiple Health-States

    Dec 1, 2023, 00:00

  • EE314 Ferric Carboxymaltose in the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Private Health Care System: Cost-Effectiveness Analysis and Budget Impact in Brazil

    Dec 1, 2023, 00:00

  • EPH198 Annual Health Insurence Treatment Cost of Polycystic Ovary Sindrome Based on Routinely Collected Financing Data Between 2010-2019

    Dec 1, 2023, 00:00

  • EE168 A Markov Model to Determine the Cost-Effectiveness of a Multi-Targeting Bacterial Gene Therapy (AUP-16) at Healing a Diabetic Foot Ulcer When Compared to the Current Standard of Care

    Dec 1, 2023, 00:00

  • P46 Drivers of Health Technology Assessment Methods and Process Reforms: An International Comparison of Real World Evidence, Patient Involvement and Discounting

    Dec 1, 2023, 00:00

  • CO183 Simulated Treatment Comparison and Matching-Adjusted Indirect Comparison of the Efficacy of Eplontersen and Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

    Dec 1, 2023, 00:00

  • EE4 Cost-Effectiveness of Andexanet Alfa Versus Prothrombin Complex Concentrate Is Likely for the Treatment of Factor Xa Inhibitor–Related Major Bleeds in the Netherlands

    Dec 1, 2023, 00:00

  • HTA255 First-in-Class Drugs in HTA: Blunder or Bliss?

    Dec 1, 2023, 00:00

  • EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa

    Dec 1, 2023, 00:00

  • SA25 Caregiver Burden in Growth Hormone Deficiency: A Targeted Review

    Dec 1, 2023, 00:00

  • RWD9 Identifying Predictors of Response Following Discontinuation of JAKi Therapy in Patients with Rheumatoid Arthritis

    Dec 1, 2023, 00:00

  • HTA253 Analysis of HTA Assessments, Usage, and Reimbursement of Newly Introduced Outpatient Drugs in the Netherlands Between 2017 and 2021 – A Secondary Data Analysis

    Dec 1, 2023, 00:00

  • MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study

    Dec 1, 2023, 00:00

  • PT26 How Aware Are Biotech and Pharmaceutical Companies of the Implementation of the New EU HTA?

    Dec 1, 2023, 00:00

  • HSD90 Beyond the Hospital Walls: Hospital at Home Programs for Cancer Patients Worldwide and the Road to Implementation in Greece

    Dec 1, 2023, 00:00

  • EE90 Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Show Substantial Healthcare Resource Utilization

    Dec 1, 2023, 00:00

  • EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective

    Dec 1, 2023, 00:00

  • HTA345 Amplifying the Patient Voi Characterising the Impact of Patient and Clinician Engagement (PACE) Meetings on SMC Decision Making

    Dec 1, 2023, 00:00

  • CO73 Overview of COA Measures in SLE Clinical Trials and Label Claims

    Dec 1, 2023, 00:00

  • HPR140 Quantifying the Impact of Novel Anti-Cancer Therapies on Health Inequalities in Survival Based on Kaplan-Meier Curves

    Dec 1, 2023, 00:00

  • EPH237 Incidence and Risk Factors for Psychiatric Disorders Across Different Health Insurance Systems in Japan

    Dec 1, 2023, 00:00

  • PT32 Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • EE114 Reductions in Travel Time and CO2 Emissions Arising From Patient Transportation to Hospitals in Ireland for Treatment With Intravenous Iron: An Analysis Comparing Ferric Derisomaltose With Ferric Carboxymaltose

    Dec 1, 2023, 00:00

  • RWD97 Systematic Identification, Access, and Utility Mapping of Asia Pacific Real-World Data Sources for Rare and Non-Rare Retinal Diseases

    Dec 1, 2023, 00:00

  • EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy

    Dec 1, 2023, 00:00

  • RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review

    Dec 1, 2023, 00:00

  • Table of Contents

    Dec 1, 2023, 00:00

  • EE118 Cost Incurred Post-Kidney Transplant: A Systematic Review

    Dec 1, 2023, 00:00

  • EE465 Sacubitril/Valsartan Vs Enalapril Use in the Outpatient Facilities Setting in Spain

    Dec 1, 2023, 00:00

  • HTA357 Cost-Comparisons, an Easier Route to NICE Recommendations?

    Dec 1, 2023, 00:00

  • EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067

    Dec 1, 2023, 00:00

  • MSR74 The Use of Matching-Adjusted Indirect Comparison for Oncology Submissions in NICE

    Dec 1, 2023, 00:00

  • HTA322 Modelling Antifibrotic Therapies for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease: Learnings from NICE Submissions from the Past Decade

    Dec 1, 2023, 00:00

  • PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

    Dec 1, 2023, 00:00

  • MT13 Digging into the Medical Technology HTA Process in Tunisia

    Dec 1, 2023, 00:00

  • HTA327 Acceptance of Real-World Evidence As Comparative Efficacy in Lieu of Trial Eviden A Review of Past NICE Appraisals in Oncology

    Dec 1, 2023, 00:00

  • PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease

    Dec 1, 2023, 00:00

  • PCR7 People Living With HIV’s Lived Experiences of Long-Acting Injectable Antiretroviral Treatment Administrations in France Show the Central Role of Hospital Nurses in Care: A Qualitative Study (PANTER)

    Dec 1, 2023, 00:00

  • EPH191 Iron Deficiency Anemia Is Associated with Colorectal and Stomach Cancer Diagnoses in Germany

    Dec 1, 2023, 00:00

  • RWD39 Comparative Effectiveness and Health Resource Utilization of Xuesaitong Soft Capsule in Patients with Stroke of Secondary Prevention in China: A Retrospective Cohort Study

    Dec 1, 2023, 00:00

  • EPH122 Global Burden of Disease Study on Chikungunya: Estimating Dalys and Cost Burden

    Dec 1, 2023, 00:00

  • EE559 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Honduras, El Salvador, Dominican Republic

    Dec 1, 2023, 00:00

  • EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)

    Dec 1, 2023, 00:00

  • PCR275 An Interpretive Phenomenological Analysis of Financial Toxicity in Indonesian Cancer Patients

    Dec 1, 2023, 00:00

  • SA74 A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

    Dec 1, 2023, 00:00

  • MSR20 Estimating Undetected Medication Errors at Care Transitions: A Framework to Support Decision-Making

    Dec 1, 2023, 00:00

  • EPH149 Prevalence, Burden of Disease, and Treatment Patterns of Vitiligo in Patients Across European Countries

    Dec 1, 2023, 00:00

  • CO171 Associations of Sex and Race with Relative Efficacy in Clinical Trials

    Dec 1, 2023, 00:00

  • HPR65 Pricing and Reimbursement Mechanisms for Advanced Therapeutic Medicinal Products in 20 Countries

    Dec 1, 2023, 00:00

  • EPH78 A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs

    Dec 1, 2023, 00:00

  • CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review

    Dec 1, 2023, 00:00

  • HTA346 The Use of Real-World Evidence in Health Technology Assessment Decisions in Sweden and the UK: A Natural Language Processing (NLP) Approach

    Dec 1, 2023, 00:00

  • EE546 Development of a Drug Price Index for Approved Cystic Fibrosis Treatments

    Dec 1, 2023, 00:00

  • HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany

    Dec 1, 2023, 00:00

  • EPH10 ICD-10 Surrogates of the Modified Frailty Index Predict Hospital Referrals in Outpatients Followed in German General Practices

    Dec 1, 2023, 00:00

  • HPR54 Policy Approaches to the Regulation and Reimbursement of Pediatric Medicines: Comparing Canadian, European, and UK Health Systems

    Dec 1, 2023, 00:00

  • EE354 Value for Money: Evaluating the Economic Benefit of a Hypothetical Disease Modifying Therapy for Alzheimer's Disease From Canadian Payer and Societal Perspectives

    Dec 1, 2023, 00:00
  • «
  • 21 (current)
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »